- Last Close 135.70
- Sector Healthcare
- Industry Biotechnology
- Investment Style Large Growth
- Day Range 130.90 – 137.40
- Year Range 74.90 – 170.50
- Market Cap 178.1980 Bil
- Volume / Avg 557,671.0 / 1.3 Mil
- Price / Sales 14.98
- Price / Book 5.67
- Forward Div Yield —
- Trailing Div Yield —
Morningstar‘s Stock Analysis 06160
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile 06160
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.
Grand Cayman, KY1-1108, CYM
Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion.
BeiGene Ltd Ordinary Shares
Karyopharm Therapeutics Inc
Kintor Pharmaceutical Ltd Ordinary Shares
|−$4.80 (3.54%)||+$0.06 (2.73%)||+$0.04 (1.01%)||—|
|178.20 Bil||257.66 Mil||1.79 Bil||—|
* Trading data in this section is delayed by at least 15 minutes.
FAQs for BeiGene Ltd Ordinary Shares Stock
No. 06160 does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
06160’s market cap is 178.20 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Learn more about market capitalization.
06160’s stock style is Large Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
Learn more about style.
06160’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare 06160’s historical performance against its industry peers and the overall market.